Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma

PURPOSE: This study aimed to evaluate the safety and efficacy of a combination of programmed death-1 (PD-1) inhibitor and regorafenib as second-line treatment for advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: We retrospectively analyzed the data of 38 patients with unresectable HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jinpeng, Jia, Yuntao, Shao, Changdong, Li, Yuanming, Song, Jinlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083010/
https://www.ncbi.nlm.nih.gov/pubmed/37041973
http://dx.doi.org/10.2147/TCRM.S400079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083010/
https://www.ncbi.nlm.nih.gov/pubmed/37041973
http://dx.doi.org/10.2147/TCRM.S400079

Ejemplares similares